A prospective study of postmenopausal hormone use and ovarian cancer risk by Danforth, K N et al.
A prospective study of postmenopausal hormone use and ovarian
cancer risk
KN Danforth*,1, SS Tworoger
1,2, JL Hecht
3, BA Rosner
1,4, GA Colditz
1,2 and SE Hankinson
1,2
1Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA;
2Department of
Epidemiology, Harvard School of Public Health, Boston, MA, USA;
3Department of Pathology, Beth-Israel Deaconess Medical Center, Boston, MA, USA;
4Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA
The relationship between postmenopausal hormone use (PMH) and ovarian cancer risk is unclear, particularly for specific hormone
formulations, but recent studies suggest that there is a positive association. We conducted a prospective observational study with
82905 postmenopausal women, including 389 ovarian cancers, in the Nurses’ Health Study from 1976 to 2002. Compared with
never users of PMH, both current and past users of X5 years had a significantly elevated risk of ovarian cancer (RR¼1.41, 95%
confidence interval (CI) 1.07–1.86 and relative risk (RR)¼1.52, 95% CI 1.01–2.27, respectively). Examined by hormone type in
continuous years, use of unopposed estrogen was associated with a significant increase in the risk of epithelial ovarian cancer (P for
trend o0.001; RR for 5-year increment of use¼1.25, 95% CI 1.12–1.38). Use of estrogen plus progestin (RR for 5-year increment
of use¼1.04, 95% CI 0.82–1.32) was not significantly associated with ovarian cancer risk. Generally, results were similar for serous
tumours (RR for 5-year increment of unopposed estrogen use¼1.23, 95% CI 1.07–1.40) and slightly stronger for endometrioid
tumours (RR for 5-year increment of unopposed estrogen use¼1.53, 95% CI 1.20–1.94). Recency of use was not significantly
associated with ovarian cancer risk, but statistical power was limited here.
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Ovarian cancer is the fifth most common cause of cancer mortality
among women in the United States (American Cancer Society,
2006), and yet few truly modifiable factors have been established.
Postmenopausal hormone (PMH) use has been examined as a
potential risk factor for ovarian cancer in several studies, but
reviews (IARC Working Group on the Evaluation of Carcinogenic
Risks to Humans et al, 1999; Riman et al, 2004; Farquhar et al,
2005) and meta-analyses (Garg et al, 1998; Coughlin et al, 2000)
have found studies to be inconsistent, as did the US Preventive
Services Task Force review of higher-quality studies (USPSTF,
2005). Recently, unopposed estrogen use has been positively
associated with ovarian cancer risk or mortality in several cohort
studies (Rodriguez et al, 2001; Lacey et al, 2002, 2006; Folsom
et al, 2004). Although estrogen plus progestin use also has been
examined in multiple studies (Lacey et al, 2002, 2006; Riman et al,
2002; Sit et al, 2002), only one cohort study reported a substantial
number of cases among long-duration estrogen plus progestin
users, finding a significant increased risk of ovarian cancer
(Lacey et al, 2006).
We evaluated the association between PMH use and ovarian
cancer in the prospective Nurses’ Health Study (NHS) over 26
years of follow-up; we examined duration, recency of use, and
PMH type for all ovarian tumours, as well as by histologic tumour
type.
MATERIALS AND METHODS
Study cohort
The NHS began in 1976, when 121701 female registered nurses in
11 US states completed a self-administered, mailed questionnaire.
At enrolment, participants were 30–55 years old. Subsequently,
follow-up questionnaires were mailed biennially to obtain updated
exposure and disease information. Information on deaths was
obtained through the post office, relatives and linkages with the
National Death Index. Through 2002, these methods yielded a
follow-up rate of 93.7% of potential person-years. The study was
approved by the Institutional Review Board of Brigham and
Women’s Hospital.
Study population
The study population was restricted to postmenopausal women.
A validation study in the NHS found self-reported menopause
to have high reproducibility (Colditz et al, 1987). Women whose
menopausal status was missing, or who reported a hysterectomy
without bilateral oophorectomy, contributed person-time from the
age at which natural menopause occurred for 90% of the cohort
(54 years for current smokers, 56 years for past or never smokers).
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NHS. Participants were excluded if they reported radiation as the
reason for menopause (n¼209), a bilateral oophorectomy
(n¼8506), or a diagnosis of cancer other than non-melanoma
skin cancer (n¼514) before the start of follow-up. Women
missing exposure or covariate information (n¼1074) were
excluded (details below), leaving 14140 eligible women in the
baseline population.
Women subsequently entered the study population as they
became postmenopausal, provided that radiation or bilateral
oophorectomy was not the cause of menopause. Participants were
censored at the earliest of: (1) development of ovarian cancer, (2)
report of any cancer other than non-melanoma skin cancer, (3)
death, or (4) the end of the study period, 6/1/2002. Person-time
with missing exposure or covariate information also was excluded.
From 1976 to 2002, 82905 postmenopausal women accumulated a
total of 966017 person-years.
Postmenopausal hormone use
PMH use was assessed in every questionnaire. In 1976, users
reported their total duration of use. As 72% of users of a known
type reported use of unopposed estrogen in 1978 (when such
details were first collected), PMH use in 1976 was classified as
unopposed estrogen. This classification probably resulted in a
small amount of misclassification of other types of PMH; however,
in a sensitivity analysis, we also re-coded PMH use in 1976 to
other/unknown type of hormone.
Ovarian cancer
Incident cases of ovarian cancer were identified through responses
to biennial questionnaires or death certificates and confirmed by
medical record review. From 1976 to 2002, there were 760 reported
cases of postmenopausal ovarian cancer. We were unable to obtain
medical records for 71 (9.3%) and did not confirm the diagnosis
upon medical record review for 135 (17.8%) women. Of the 554
confirmed cases, 492 were epithelial tumours (88.8%). After
applying exclusion criteria (e.g., prior diagnosis of another
cancer), we were left with 389 cases of primary epithelial ovarian
cancer.
Histologic type, as coded from pathology reports by a
gynecologic pathologist (JLH), had the following distribution:
233 serous/poorly differentiated (hereafter referred to as serous),
60 endometrioid, 35 mucinous, 19 clear-cell and 42 other/unknown
subtype. Of the 389 cases, 353 were invasive and 36 were of low
malignant potential (18 serous, 15 mucinous, 2 endometrioid and 1
clear cell).
Covariates
Age and time period were used as stratification variables in the
Cox proportional hazards models. Based on previous literature,
the following covariates were forced into the multivariate
models: duration of oral contraceptive use (continuous), parity
(continuous), tubal ligation (yes/no), age at natural menopause
(continuous) and age at menarche (o12, 12, 13, 14, X15 years).
The complete case method (restricting the analysis to participants
with data on the exposure and all covariates) was used, except
that women with a hysterectomy were included; the population
was restricted to women with natural menopause in secondary
analyses.
In addition, the following potential confounders were not
included in the final models: vigorous physical activity, smoking,
alcohol consumption, caffeine intake, lactose/galactose consump-
tion, perineal talc use, breastfeeding, simple hysterectomy, use of
non-steroidal anti-inflammatory medications other than aspirin
and family history of breast cancer. Data on family history of
ovarian cancer, first collected in 1992, was evaluated as a potential
confounder by examining its distribution across PMH categories
in 1992. Fat intake and body mass index (BMI) were not
considered confounders because they were not associated with
postmenopausal ovarian cancer in previous NHS analyses (Bertone
et al, 2002; Fairfield et al, 2002). However, BMI and having an
intact reproductive system (no tubal ligation or hysterectomy)
were evaluated as potential effect modifiers.
Data analysis
Multivariate Cox proportional hazards regression models were
used to estimate RRs and 95% CIs. The association with ovarian
cancer was examined for status of PMH use (never, past and
current), total duration and time since last use. In addition,
analyses were performed by type-specific duration in continuous
years, simultaneously including all PMH types in the models
(unopposed estrogen, estrogen plus progestin, other PMH).
Results have not been presented for the ‘other PMH’ group
because it represents a heterogeneous group of hormones,
including non-conjugated estrogens, patch hormones, and vaginal
hormones, as well as person-time for which hormone type was not
reported.
Primary analyses included all tumours (invasive and low
malignant potential), but sensitivity analyses restricted cases to
invasive tumours. Separate analyses were performed for serous
and endometrioid tumour subtypes, but owing to small numbers,
those for mucinous tumors (n¼35) were adjusted only for age,
and clear cell tumors (n¼19) were not evaluated.
RESULTS
Description of the study population
Population characteristics are presented for 1992 (Table 1), the
approximate midpoint of the study, and the first year in which
family history of ovarian cancer was collected. The mean age
among study participants in 1992 was 61.2 years. The average
duration of hormone use was longer among current unopposed
estrogen users than current estrogen plus progestin users (9 vs 6
years, respectively). Compared to never users, PMH users were
more likely to have used oral contraceptives or had a simple
hysterectomy. As expected, current users of unopposed estrogen
were substantially more likely to have had a hysterectomy than
current users of estrogen plus progestin. Correspondingly, tubal
ligation was more common among users of estrogen plus progestin
than users of unopposed estrogen. The distribution of other risk
factors was generally similar across PMH classifications. There was
no substantial variation by family history of ovarian cancer across
exposure groups.
Multivariate results
Results from the age-adjusted and multivariate models were nearly
identical, indicating minimal confounding by other risk factors
(Table 2). Neither current (RR¼1.24, 95% CI 0.97–1.59) nor past
(RR¼1.00, 95% CI 0.77–1.31) use of PMH was significantly
associated with ovarian cancer risk compared with never use.
For serous tumours, current use of PMH was associated with a
significant increase in risk (RR¼1.43, 95% CI 1.04–1.96)
compared to never use. Risk was non-significantly increased for
endometrioid tumors for current (RR¼1.61, 95% CI 0.85–3.05)
and past (RR¼1.68, 95% CI 0.85–3.33) use compared with never
use. Results were similar when models were restricted to invasive
tumours (data not shown).
When analyses were stratified by total duration of PMH use (o5
and X5 years), increased risk was observed among both current
(RR¼1.41, 95% CI 1.07–1.86) and past (RR¼1.52, 95% CI 1.01–
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(Table 3). Results were similar for serous tumors, although
statistically significant only for current users of greater than five
years (RR¼1.66, 95% CI 1.17–2.36). Results generally were
stronger for endometrioid tumours, although the increased risk
was statistically significant for past (RR¼3.59, 95% CI 1.41–9.14),
but not current (RR¼1.86, 95% CI 0.89–3.91), users of 5 or more
years compared with never users.
Combining current and past use, continuous years of unopposed
estrogen use were significantly associated with increased risk
(P for trend o0.001, RR¼1.25 for a 5-year increment of use, 95%
CI 1.12–1.38), whereas continuous years of estrogen plus progestin
use were not (P for trend¼0.77, RR¼1.04 for a 5-year increment
of use, 95% CI 0.82–1.32) (Table 4). Results were similar when
hormone use in 1976 was re-classified as unknown/other type
(data not shown) and when terms were added for past and current
use (data not shown). The increased risk observed with continuous
years of unopposed estrogen use was generally similar for serous
tumours (RR for 5-year increment of unopposed estrogen
use¼1.23, 95% CI 1.07–1.40) and slightly stronger for endo-
metrioid tumours (RR for 5-year increment of unopposed estrogen
use¼1.53, 95% CI 1.20–1.94), although there was a limited
number of cases for the endometrioid analysis. When mucinous
tumours were examined in age-adjusted analyses, point estimates
suggested that past (RR¼0.72, 95% CI 0.30–1.76) and current
(RR¼0.72, 95% CI 0.31–1.67) users had a reduced risk compared
with never users, although results were not significant and based
on few cases.
In analyses restricted to women exclusively using one hormone
formulation, unopposed estrogen use of five or more years was
associated with an increased risk compared with never use
(RR¼2.04, 95% CI 1.41–2.97), whereas estrogen plus progestin
use of five or more years was not (RR¼0.93, 95% CI 0.47–1.83)
(Table 5). However, there were only ten cases among estrogen plus
progestin users of X5 years. Results were similar for unopposed
estrogen use among women reporting a hysterectomy and estrogen
plus progestin use among women with intact uteri (data not
shown).
Time since last use was not significantly associated with risk.
Neither users who quit within the previous three years (RR¼1.04,
95% CI 0.71–1.53) nor those who stopped over three years ago
(RR¼0.86, 95% CI 0.60–1.22) were at a significantly increased
risk of ovarian cancer. Based on the significant association
observed with duration, a recency effect would most likely be
seen primarily among long-term users. Although limited by small
numbers, when we examined the effects of recency and duration
together, point estimates suggested an increase in risk among users
of five or more years that decreased over time (RR¼1.62 among
the most recent quitters and RR¼1.35 among those who quit over
3 years ago, with 17 and 11 cases respectively).
No substantial differences were observed when stratifying on
BMI (o25, 25–29, X30kgm
 2) or an intact reproductive system
(i.e., no prior hysterectomy or tubal ligation) (data not shown).
Results were also similar among women reporting natural
menopause, although the association with unopposed estrogen
use was slightly stronger (RR¼1.40 for a 5-year increment of use,
95% CI 1.09–1.80).
Table 1 Age and age-standardised characteristics by postmenopausal hormone use and hormone type in the Nurses’ Health Study, 1992
a
PMH status Current PMH users
Never user
(n¼20853)
Past user
(n¼10053)
Current user
(n¼16831)
Estrogen only
(n¼4315)
Estrogen+Progestin
(n¼7394)
Age, mean, years 61 64 60 62 58
Duration of PMH use, mean, years 0 3 7 9 6
Duration of OC use (%)
Never 66 58 55 54 52
o 3 years 18 23 22 23 22
X3 years 17 20 23 23 26
Parity
Parous women (%) 94 93 93 94 93
Mean no. of children (among parous) 3 3 3 3 3
Family
b history of ovarian cancer (%) 3 3 2 3 3
Had a simple hysterectomy (%) 5 12 19 47 2
Had a tubal ligation (%) 13 14 14 10 17
Age at menarche, mean, years 13 13 13 13 13
Age at natural menopause, mean, years 50 49 50 49 50
Abbreviations: PMH, postmenopausal hormone; OC, oral contraceptive.
aCharacteristics are presented for the 47737 nurses who met the study eligibility criteria in 1992; all
factors except age were age-standardised in 5-year intervals.
bMother or sister had ovarian cancer according to nurse’s response to questionnaire.
Table 2 Use of postmenopausal hormones and epithelial ovarian cancer
risk; all cases combined and by histologic type
a
Never user Past user Current user
All epithelial ovarian tumours
No. of cases 167 88 134
Person-years 455200 210778 300039
Age-adjusted RR
(95% CI)
1.00 (referent) 1.00 (0.77, 1.31) 1.23 (0.97, 1.57)
Multivariate
b RR
(95% CI)
1.00 (referent) 1.00 (0.77, 1.31) 1.24 (0.97, 1.59)
Serous tumours
No. of cases 96 51 86
Multivariate
b RR
(95% CI)
1.00 (referent) 0.98 (0.69, 1.40) 1.43 (1.04, 1.96)
Endometrioid tumours
No. of cases 21 16 23
Multivariate
b RR
(95% CI)
1.00 (referent) 1.68 (0.85, 3.33) 1.61 (0.85, 3.05)
Abbreviations: RR, relative risk; CI, confidence interval.
aResults by histologic type are
presented for serous/poorly differentiated and endometrioid tumors only due to
small numbers for the other histologic types.
bAdjusted for: age, parity, duration of
oral contraceptive use, tubal ligation, age at natural menopause, age at menarche.
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In this prospective study, we observed a positive association
between long duration of PMH use and ovarian cancer risk,
regardless of whether use was current or past. More specifically,
duration of unopposed estrogen use was positively associated with
risk, whereas estrogen plus progestin use was not; the association
was stronger for endometrioid tumours, although numbers were
small.
In a collaborative re-analysis of 12 case–control studies, no
association was found with duration of PMH use in either hospital-
based (OR¼0.90 for a 5-year increment of use, P¼0.37)
or population-based (OR¼1.10 for a 5-year increment of use,
P ¼ 0.21) studies (Whittemore et al, 1992). Meta-analyses
(Garg et al, 1998; Coughlin et al, 2000) and certain case–control
studies (Weiss et al, 1982; Riman et al, 2002) also failed to find
a significant trend with duration of use, although some found a
positive association (Risch, 1996) or suggested a positive trend
(Kaufman et al, 1989; Bosetti et al, 2001).
Recently, four prospective studies found that longer durations
of PMH use were associated with ovarian cancer risk or
death (Rodriguez et al, 2001; Lacey et al, 2002; Folsom et al,
2004; Lacey et al, 2006). In two, ovarian cancer risk (Lacey et al,
2006) and mortality (Rodriguez et al, 2001) were increased
among unopposed estrogen users of X10 years but not among
users of o10 years; elevations in mortality were similar for current
and past long-duration users (Rodriguez et al, 2001). Two other
cohort studies observed increases in risk with shorter durations of
use: in the Breast Cancer Detection Demonstration Project
(BCDDP, n¼329 cases), unopposed estrogen use was significantly
associated with risk (RR¼1.40 for 5 years use, converted from a 1-
year estimate), with similar results for recent and former
long-duration users (Lacey et al, 2002). In another prospective
study, current users of unopposed estrogens for 45years had a
significantly elevated risk (RR¼2.53, 95% CI 1.44–4.45, n¼16
cases); although risk was not increased among long-duration past
users, there were only four cases (Folsom et al, 2004). Findings
from recent case–control studies also generally support a positive
association with long-duration PMH use (Glud et al, 2004;
Mills et al, 2004; Pike et al, 2004; Riman et al, 2004; Moorman
et al, 2005).
We found a strong association with duration of PMH use and
risk among current and past users of five or more years duration.
With both duration and status of use (never, past, current) in the
same model, only duration was statistically significant (data not
shown). Overall, the significant increase in risk appeared to be
driven largely by duration rather than by status of use. This
contrasts with breast cancer PMH findings, where the increased
risk is confined to current users (Colditz et al, 1995; Collaborative
Group on Hormonal Factors in Breast Cancer, 1997; Beral et al.,
2003), although the comparison is limited by the relative paucity of
data on recency effects for ovarian cancer.
Only recently have studies had sufficient case numbers to
evaluate associations for estrogen and progestin use. A Swedish
case–control study (n¼655 cases) found that use of estrogen plus
sequential progestin was associated with an increased risk, whereas
estrogen plus continuous progestin was not (Riman et al, 2002).
However, results from the women’s health initiative (WHI), a
randomized clinical trial of estrogen plus continuous progestin
(n¼32 cases), were consistent with an increase in risk (RR¼1.58,
95% CI 0.77–3.24), although not statistically significant (Anderson
et al, 2003). Another cohort study found an increased risk
associated with both sequential (RR¼3.09, 95% CI 1.68–5.68;
Table 3 Total duration of postmenopausal hormone use and risk of epithelial ovarian cancer; all cases combined and by histologic type
a
Past user Current user
Never user o5 years use X5 years use o5 years use X5 years use
All epithelial ovarian tumours
No. of cases 167 57 31 40 94
Person-years 455200 164558 46220 129669 170370
Age-adjusted RR (95% CI) 1.00 (referent) 0.87 (0.64, 1.18) 1.50 (1.01, 2.22) 1.00 (0.70, 1.43) 1.38 (1.06, 1.82)
Multivariate
b RR (95% CI) 1.00 (referent) 0.88 (0.64, 1.19) 1.52 (1.01, 2.27) 1.01 (0.70, 1.44) 1.41 (1.07, 1.86)
Serous tumours
No. of cases 96 32 19 23 63
Multivariate
b RR (95% CI) 1.00 (referent) 0.83 (0.55, 1.25) 1.60 (0.95, 2.68) 1.09 (0.68, 1.75) 1.66 (1.17, 2.36)
Endometrioid tumours
No. of cases 21 9 7 8 15
Multivariate
b RR (95% CI) 1.00 (referent) 1.25 (0.56, 2.80) 3.59 (1.41, 9.14) 1.38 (0.59, 3.25) 1.86 (0.89, 3.91)
Abbreviations: RR, relative risk; CI, confidence interval.
aResults by histologic type are presented for serous/poorly differentiated and endometrioid tumours only due to small
numbers for the other histologic types.
bAdjusted for age, parity, duration of oral contraceptive use, tubal ligation, age at natural menopause and age at menarche.
Table 4 Continuous years of estrogen and estrogen plus progestin use
and risk of epithelial ovarian cancer; all cases combined and by histologic
type
a
Continuous RR converted to 5-year
increment
Estrogen only
Estrogen plus
progestin
All ovarian tumours
Cases
b 137 82
Age-adjusted RR (95% CI) 1.23 (1.11, 1.35) 1.05 (0.82, 1.33)
Multivariate
c RR (95% CI) 1.25 (1.12, 1.38) 1.04 (0.82, 1.32)
Serous tumours
Cases
b 89 49
Multivariate
c RR (95% CI) 1.23 (1.07, 1.40) 1.12 (0.84, 1.51)
Endometrioid tumours
Cases
b 23 15
Multivariate
c RR (95% CI) 1.53 (1.20, 1.94) 1.04 (0.53, 2.03)
Abbreviations: RR, relative risk; CI, confidence interval; PMH, postmenopausal
hormone.
aResults by histologic type are presented for serous/poorly differentiated
and endometrioid tumours only due to small numbers for the other histologic types.
bSome participants (and therefore cases) contribute to multiple categories
simultaneously because they used estrogen only, estrogen plus progestin and/or
other PMH formulations.
cAdjusted for age, parity, duration of oral contraceptive use,
tubal ligation, age at natural menopause and age at menarche.
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yn¼13 cases) and continuous (RR¼1.82, 95% CI 1.03–3.23; n¼15
cases) estrogen plus progestin use of X5 years in women without a
hysterectomy (Lacey et al, 2006).
In contrast, a cohort study in Norway found no association with
use of estrogen plus progestin (RR¼1.5, 95% CI 0.9–2.6; n ¼ 23
cases) (Bakken et al, 2004), and nor did the BCDDP study. Data
suggested that unopposed estrogen, followed by estrogen plus
progestin, was associated with risk; however, the effects of the
different hormones could not be disentangled (Lacey et al., 2002).
In our study, when simultaneously including terms for years of
unopposed estrogen, estrogen plus progestin and other PMH use,
only unopposed estrogen use was significantly associated with risk;
results were consistent among users of a single hormone type.
However, duration of estrogen plus progestin use was on an
average shorter than use of unopposed estrogen, and the upper
confidence limits were similar to those observed for unopposed
estrogen use. Further studies about long-duration estrogen plus
progestin use are therefore needed, given its more recent
introduction to the market, particularly those focused on
sequential or continuous hormone regimens.
Among the few analyses by histologic type, one suggested that
PMH use might specifically increase risk of endometrioid tumours
(Weiss et al, 1982). Other prospective studies either have not
examined tumour subtype (Rodriguez et al, 2001; Anderson et al,
2003; Bakken et al, 2004; Folsom et al, 2004; Lacey et al, 2006) or
had incomplete information on histology (Lacey et al, 2002).
Despite limited power, in our study, the association with
unopposed estrogen use appeared slightly stronger for endome-
trioid tumours. In age-adjusted analyses, point estimates suggested
PMH use might decrease the risk of mucinous tumours, consistent
with some (Weiss et al, 1982; Risch, 1996), but not all (Riman et al,
2002), previous reports. Although statistical comparisons between
the subtypes were precluded by sample size, our findings are
consistent with epidemiologic and biologic data. Endometrioid
tumours are histologically similar to endometrial tissue (Kumar
et al, 1997), and unopposed estrogen use increases the risk of
endometrial cancer (Fraser et al, 1998). Mucinous tumors are sub-
classified as those that resemble colonic or endocervical epithelium
(Kumar et al, 1997). PMH use has been associated with decreased
colon cancer risk (Nelson et al, 2002) but not with altered cervical
cancer risk (Weiss and Hill, 1996).
The mechanism by which PMH might affect ovarian cancer risk
is unknown. One theory posits that high levels of gonadotropins
increase risk, implying that PMH use might decrease risk by
reducing these levels (follicle-stimulating hormone (FSH) and
leutinising hormone (LH)), but as the declines associated with
PMH use are small, the benefits might be outweighed by estrogen-
induced proliferation of ovarian cells (Cramer and Welch, 1983;
Fraser et al, 1998); it has been estimated that as many as 60% of
ovarian tumours are estrogen receptor-positive (Cunat et al, 2004).
Breast cancer research also suggests that estrogen may be directly
genotoxic (Ho, 2003). Although it is premature to conclude that
estrogen plus progestin use is unassociated with ovarian cancer
risk, particularly given the conflicting findings, research on
ovulating macaques suggests that progesterone offsets the effect
of unopposed estrogen use by increasing apoptosis in the ovary
(Rodriguez et al, 1998), possibly by altering levels of TGF-b,a
regulator of apoptosis (Rodriguez et al, 2002). The progesterone in
these animal studies may have different effects from the progestins
commonly used in PMH formulations, but a mechanism is
suggested, given that progesterone receptors are normally found
in ovarian epithelium (Risch, 1998).
Our analysis has several strengths. The NHS is one of only a few
prospective studies of PMH use and ovarian cancer, and
associations could be examined by hormone type. Information
on exposures and confounders is updated through biennial
questions, and follow-up of the cohort is high. The nurses are a
relatively homogenous group, with similar education and access to
health care, reducing concerns about confounding. Although
family history of ovarian cancer was first collected in 1992, this
did not vary substantially across exposure. Histologic tumour type
was coded by a gynecologic pathologist and was available for most
cases.
Nurses’ Health Study (NHS) participants are not a representa-
tive sample of the general population. While it is unlikely that
the observed associations would differ in other women, studies
covering different race/ethnicity and socioeconomic status are
warranted. Generalisability may also be limited by the variations in
PMH formulations across countries. We had limited power to look
at non-oral formulations of PMH, which are more commonly used
outside the US (Ho, 2003). Small numbers prevented evaluation of
different regimens of estrogen plus progestin and limited the
analysis of recency of use.
In conclusion, we found that use of PMH was positively
associated with risk of epithelial ovarian cancer. With other recent
studies, our findings suggest that women should be counseled
about the potential long-term increase in ovarian cancer risk with
extended use of unopposed estrogen. Evidence is insufficient to
say whether estrogen plus progestin or very short durations of
unopposed estrogen use are associated with risk. Available
findings indicate that ovarian cancer is one of several conditions
that should be considered by women when weighing the risk and
benefits of PMH use.
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Table 5 Risk of epithelial ovarian cancer among exclusive users of one hormone type (estrogen only and estrogen plus progestin)
Estrogen only
a Estrogen plus progestin
a
o5 years use X5 years use o5 years use X5 years use
All epithelial ovarian tumours
No. of cases 39 43 22 10
Age-adjusted (95% CI) 0.94 (0.66, 1.34) 1.81 (1.28, 2.56) 1.03 (0.64, 1.67) 0.92 (0.47, 1.79)
Multivariate
b RR (95% CI) 0.98 (0.68, 1.40) 2.04 (1.41, 2.97) 1.03 (0.64, 1.66) 0.93 (0.47, 1.83)
Abbreviations: RR, relative risk; CI, confidence interval; PMH, postmenopausal hormone.
aModels include never PMH users and users of one hormone type only (exclusive users
of unopposed estrogen and exclusive users of estrogen plus progestin).
bAdjusted for age, parity, duration of oral contraceptive use, tubal ligation, age at natural menopause and
age at menarche.
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